Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy
M Tsiang, JF Rooney, JJ Toole, CS Gibbs - Hepatology, 1999 - journals.lww.com
In a recent phase II clinical study, 13 chronic hepatitis B-infected patients treated daily with
30 mg adefovir dipivoxil for 12 weeks displayed a median 4.1–log 10 decrease in plasma
hepatitis B virus (HBV)–DNA levels. The decline of viral load during therapy displayed a
biphasic kinetic profile that was modeled to determine the efficacy of inhibition of viral
production, as well as kinetic constants for the clearance of free virus and the loss of infected
cells. Viral production was suppressed with an efficacy of 0.993±0.008, indicating that only …
30 mg adefovir dipivoxil for 12 weeks displayed a median 4.1–log 10 decrease in plasma
hepatitis B virus (HBV)–DNA levels. The decline of viral load during therapy displayed a
biphasic kinetic profile that was modeled to determine the efficacy of inhibition of viral
production, as well as kinetic constants for the clearance of free virus and the loss of infected
cells. Viral production was suppressed with an efficacy of 0.993±0.008, indicating that only …